Rsearch Focus - Vaccines

		Hepatitis E
		As clinical manifestation and disease progression, infection with Hepatitis E is similar to that with Hepatitis A. However, severe form of hepatitis is easier to develop among Hepatitis E, especially when the individual is super-infected with another hepatitis viruses and chronic hepatitis develops. The overall mortality ranges from 0.5% - 4.0% and may reach a rate of 20% during pregnancy in the 3rd trimester.

		A recombinant Hepatitis E vaccine based on E. Coli expression system was developed in Wantai Biological Pharmacy Enterprise. It will enter Phase I clinical trial at the end of 2004.


		Vaccine Characteristics and Features

		All research activities are preformed according to the safety guidelines of FDA and the European Union The active component 每 recombinant HEV antigen exists mainly in a way of Virus like Particles (VLPs) that can simulate major neutralized epitopes of native HEV The ED50 is below 0.25 micrograms (mouse), and the protective efficacy is 83% and 100% respectively against developing of symptom and infection of Hepatitis E in rhesus model


		Hepatitis E Vaccine Development Timeline



		Human Papilloma Virus (HPV)Vaccine


		In development